Download Gynecologic Cancer

SWOG
PUBLICATIONS LIST
GYN COMMTTEE (disbanded)
2017
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
Manuscript Published/Accepted (2017)
(none)
Abstracts Published/Presented/ Accepted (2017)
(none)
SWOG
PUBLICATIONS LIST
GYN COMMTTEE (disbanded)
2016
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
Abstracts Published/Accepted (2016)
NCIC OV.21
OV21/PETROC: A randomized Gynecologic Cancer
Intergroup (GCIG) phase II study of intraperitoneal
(IP) versus intravenous (IV) chemotherapy following
neoadjuvant chemotherapy and optimal debulking
surgery in epithelial ovarian cancer (EOC). H Mackay,
CJ Gallagher, WR Parulekar, JA Ledermann, DK
Armstrong, C Gourley, I Romero, A Feeney, P
Bessette, M Hall, JI Weberpals, G Hall, SK Lau,
P Gauthier, M Fung-Kee-Fung, EA Eisenhauer, C
Winch, D Tu, DM Provencher. J Clin Oncol 34,
2016 (suppl; abstr LBA5503).
http://abstract.asco.org/176/AbstView_176_168863.html
2/1/12
SWOG
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE (disbanded)
2014
________________________________________________________________________________________________________
(DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GYN MANUSCRIPT PUBLISHED/ACCEPTED (2014)
S0904
Randomized phase II study of docetaxel plus vandetanib
3/15/10
(V+D) versus docetaxel followed by vandetanib (D --> V) in
patients with persistent or recurrent epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma (OC): SWOG S0904. R
Coleman, J Moon, A Sood, W Hu, D Branham, J Delmore, A
Bonebrake, G Anderson, S Chambers, M Markman. European
Journal of Cancer 2014 Apr 4 [Epub ahead of print].
PMID24709487.
http://www.ncbi.nlm.nih.gov/pubmed/24709487
8/1/11
SWOG
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE
2013
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
None (2013)
SWOG
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE (disbanded)
2012
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GYN ABSTRACTS PUBLISHED (2012)
S0904
Randomized phase II study of docetaxel plus vandetanib
3/15/10
(V+D) versus docetaxel followed by vandetanib (D --> V) in
patients with persistent or recurrent epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma (OC): SWOG S0904.
R Coleman, J Moon, A Sood, D Branham, J Delmore, A
Bonebrake, G Anderson, D Alberts, M Markman.
American Society of Clinical Oncology 2012 Annual
Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
J Clin Oncol 30, 2012 (suppl; abstr 5015).
http://abstract.asco.org/AbstView_114_94269.html
8/1/11
SWOG
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE
2011
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
GYN MANUSCRIPTS PUBLISHED (2011)
(none)
GYN ABSTRACTS PUBLISHED/PRESENTED (2011)
(none)
SWOG
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE
2010
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED (2010)
S0013
Prospective evaluation of an in vitro radiation resistance
9/15/00
11/15/03
assay in locally advanced cancer of the uterine cervix.
L Randall-Whitis, BJ Monk, J Moon, R Parker, M Al-Ghazi,
S Wilczynski, JP Fruehauf, M Markman, RA Burger.
Gynecologic Oncology, 119(3):417-421, 2010.
PMID20846714; PMC2978536
http://www.ncbi.nlm.nih.gov/pubmed?term=randall%20l%20radiation%20resistance
S0200
Single agent carboplatin versus carboplatin plus pegylated
Liposomal doxorubicin in recurrent ovarian cancer: final
survival results of a SWOG (S0200) phase 3 randomized
trial. M Markman, J Moon, S Wilczynski, AM Lopez,
KM Rowland, DP Michelin, VJ Lanzotti, GL Anderson,
DS Alberts. Gynecologic Oncology 116(3):323-325,
2010. PMC2836168; PMID20044128
http://www.ncbi.nlm.nih.gov/pubmed/20044128
8/15/02
12/15/04
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GYNECOLOGIC COMMITTEE
2009
________________________________________________________________________________________________________
DATE
DATE
PROTOCOL
PROTOCOL
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
CLOSED
________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED (2009)
S0009
Chemotherapy resistance as a predictor of progression3/15/01
free survival in ovariancancer patients treated with
neoadjuvant chemotherapy and surgical cytoreduction
followed by intraperitoneal chemotherapy: a Southwest Oncology
Group study. AD Tiersten, J Moon, HO Smith, SP Wilczynski,
WR Robinson, M Markman, DS Alberts. Not accepted by
International Journal of Gynecologic Oncology;
Oncology 77(6):395-399, 2009. PMC2837883;
PMID:20130422
2/1/06
S0009
Phase II evaluation of neoadjuvant chemotherapy
and debulking followed by intraperitoneal chemotherapy
in women with stage III and IV epithelial ovarian, fallopian
tube or primary peritoneal cancer: Southwest Oncology
Group Study S0009. AD Tiersten, PY Liu, HO Smith, SP
Wilcznyski, WR Robinson, M Markman, DS Alberts.
Gynecologic Oncology; 112(3):444-449, 2009
PMID: 19138791
3/15/01
2/1/06
S9701
Impact on survival of 12 versus 3 monthly cycles of
paclitaxel (175 mg/m2) administered to patients
with advanced ovarian cancer who attained a complete
response to primary platinum-paclitaxel: follow-up of a
Southwest Oncology Group and Gynecologic Oncology
Group phase 3 trial. M Markman , PY Liu , J Moon ,
BJ Monk , L Copeland , S Wilczynski, D Alberts.
Gynecologic Oncology 114(2):195-198, 2009.
PMID: 19447479
11/15/97
12/1/01
S9912
(2649)
Southwest Oncology Group trial S9912: Intraperitoneal
cisplatin and paclitaxel plus intravenous paclitaxel and
pegylated liposomal doxorubicin as primary chemotherapy
of small-volume residual stage III ovarian cancer.
HO Smith, J Moon, SP Wilczynski, AD Tiersten, EV
Hannigan, WR Robinson, SE Rivkin, GL Anderson,
PY LIU, M Markman. Gynecologic Oncology 114(2):
206-209, 2009. PMID: 19464730
10/1/00
8/15/05
G0182
(2564)
Evaluation of new platinum-based treatment
regimens in advanced-stage ovarian cancer, a
phase III trial of the Gynecologic Cancer InterGroup (GCIC). M Bookman, MF Brady, WP McGuire,
P Harper, D Alberts, M Friedlander, N Colombo,
J Fowler, PA Argenta, K DeGeest, D Mutch,
RA Burger, AM Swart, EL Trimble, C AccarioWinslow, L Roth. Journal of Clinical Oncology
27(9):1419-1425, 2009. PMID: 19224846
8/15/01
9/1/04
ABSTRACTS PUBLISHED/PRESENTED (2009)
S0009
(2675)
Chemotherapy resistance as a predictor of progression3/15/01
free survival in ovarian cancer patients treated with
neoadjuvant chemotherapy and surgical cytoreduction
followed by intraperitoneal chemotherapy: A Southwest
Oncology Group Study. Danielle Knight, AD Tiersten,
PY Liu, HO Smith, SP Wilczynski, WR Robinson, M Markman,
JP Fruehauf, DS Alberts. Poster presentation, Western Association
of Gynecologic Oncologists 2009 Annual Meeting, Vancouver,
Canada, June 24-27, 2009.
2/1/06
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GYNECOLOGIC ONCOLOGY
2008
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
9/1/90
8797
(2625)
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systemic review and
meta-analysis of individual patient data from 18 randomized
trials. C Vale, JF Tierney, LA Stewart, M Brady, K Dinshaw,
A Jakobsen, MK Parmar, G Thomas, T Trimble, DS Alberts,
H Chen, S Cikaric, PJ Eifel, M Garipagaoglu, H Keys,
N Kantardzic, P Lal, R Lanciano, F Leborgne, V Lorvidhaya,
H Onishi, RG Pearcey, E Pras, K Roberts, PG Rose, G
Thomas, CW Whitney. Journal of Clinical Oncology
26(35):5802-5812, 2008. PMID: 19001332
S0200
(2383)
Randomized trial of pegylated liposomal doxorubicin (PLD)
08/15/02
plus carboplatin versus carboplatin in platinum-sensitive
(PS) patients with recurrent epithelial ovarian or peritoneal
carcinoma after failure of initial platinum-based chemotherapy
(Southwest Oncology Group Protocol S0200). DS Alberts,
PY Liu, SP Wilczynski, MC Clouser, AM Lopez, DP Michelin,
VJ Lanzotti, M Markman. Gynecologic Oncology 108:90-94,
2008. PMID: 17949799
12/15/96
12/15/04
ABSTRACTS PUBLISHED/PRESENTED
S0009
(2621)
*S0013
(2677)
*Presented
Phase II evaluation of neoadjuvant chemotherapy and
3/15/01
2/1/06
debulking followed by intraperitoneal chemotherapy in
women with stage III and IV epithelial ovarian, fallopian
tube or primary peritoneal cancer: Southwest Oncology
Group study S0009. AD Tiersten, PY Liu, HO Smith,
SP Wilczynski, WR Robinson, M Markman, DS Alberts.
Gynecologic Oncology 108(3) Suppl. 1:S3, 2008.
http://www.sciencedirect.com/science?_ob=PublicationURL&_tockey=%23TOC%236814
%232008%23998919996.8998%23680475%23FLA%23&_cdi=6814&_pubType=J&_auth
=y&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=9917485493be
1845dc88062ff4d90daf
Prospective evaluation of an in vitro radiation resistance
Assay in cervical cancer: a Southwest Oncology Group
study. LM Randall, RA Burger, J Moon, S Wilczynski,
BJ Monk, R Parker, JP Fruehauf, RS Lavey, EH Radany,
M Markman Oral presentation at 2008 annual
meeting of International Gynecologic Cancer Society.
Gynecologic Oncology 108(3) Suppl. 1:S3, 2008.
9/15/00
11/15/03
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
S9701
(2391)
An early signal of CA-125 progression for ovarian cancer
patients receiving maintenance treatment after complete
clinical response to primary therapy. PY Liu, DS Alberts,
BJ Monk, M Brady, J Moon, M Markman. Journal of Clinical
Oncology 25(24):3615-3620, 2007.
GYN
S0211
(2355)
Phase II trial of imatinib mesylate in recurrent, biomarker
GYN
positive, ovarian cancer (Southwest Oncology Group
Protocol S0211). DS Alberts, PY Liu, SP Wilczynski, A Jang,
J Moon, JH Ward, JT Beck, M Clouser, M Markman.
International Journal of Gynecological Cancer 17:784-788,
2007.
11/15/97
12/01/01
4/15/02
01/01/06
8/15/02
12/15/04
ABSTRACTS PUBLISHED/PRESENTED
S0200
(2344)
*Presented
Phase III randomized trial of pegylated liposomal doxorubicin GYN
(PLD) plus carboplatin versus carboplatin in platinum-sensitive
(PS) patients with recurrent epithelial ovarian or peritoneal
carcinoma after failure of initial platinum-based chemotherapy:
Southwest Oncology Group Protocol S0200. DS Alberts,
PY Liu, S Wilczynski, M clouser, A Lopez, M Lange, V Lanzotti,
M Markman. Proc of the American Society of Clinical Oncology,
Journal of Clinical Oncology 25(18S):#5551, 2007.
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8412
(2368)
Significance of early changes in the serum CA-125 antigen
level on overall survival in advanced ovarian cancer. M
Markman, M Federico, PY Liu, E Hannigan, D Alberts.
Gynecologic Oncology 103:195-198, 2006.
GYN
11/25/85
5/1/89
8790
(2167)
Randomized trial of adjuvant intraperitoneal alpha-interferon
GYN
in stage III ovarian cancer patients who have no evidence of
disease after primary surgery and chemotherapy: an intergroup
study. DS Alberts, EV Hannigan, PY Liu, C Jiang, S Wilczynski,
L Copeland, M Markman. Gynecologic Oncology 100:133-138, 2006.
3/1/88
6/15/99
S9701/9326
(2263)
Pretreatment CA-125 and risk of relapse in advanced
ovarian cancer. M Markman, PY Liu, M Rothenberg,
BJ Monk, M Brady, DS Alberts. Journal of Clinical
Oncology 24(9):1454-1458, 2006.
GYN
S9717
(2072)
Tirapazamine plus cisplatin in advanced or recurrent
carcinoma of the uterine cervix: a Southwest Oncology
Group study. HO Smith, CS Jiang, GR Weiss, AV Hallum III,
PY Liu, WR Robinson III, PC Cheng, SA Scudder,
M Markman, DS Alberts. International Journal of
Gynecological Cancer 16:298-305, 2006.
GYN
8/15/98
8/15/00
G0167
(2488)
Concurrent endometrial carcinoma in women with a
biopsy diagnosis of atypical endometrial hyperplasia:
A Gynecologic Oncology Group Study. CL Trimble,
J Kauderer, R Zaino, S Silverberg, PC Lim, JJ Burke,
DS Alberts, J Curtin. Cancer 106(4):812-819, 2006.
PMID: 16400639
GYN
7/15/01
2/24/03
ABSTRACTS PUBLISHED/PRESENTED
S9701
(2237)
A modified CA-125 progression criterion in ovarian cancer
GYN
(OC) patients (pts) receiving maintenance treatment following
complete clinical response (cCR) to primary therapy. P Liu,
J Moon, DS Alberts, BJ Monk, M Brady, M Markman.
Proc of the American Society of Clinical Oncology,
Journal of Clinical Oncology 24(18S):#5080, 2006.
11/15/97
12/01/01
S9701
(2238)
Survival (S) of ovarian cancer (OC) patients (pts) treated
on SWOG 9701/GOG178: 12 versus (v) 3 cycles (c) of
monthly single-agent paclitaxel (PAC) following attainment
of a clinically –defined complete response (CR) to platinum
(PLAT)/PAC. M Markman, PY Liu, S Wilczynski, B Monk,
LJ Copeland, D Alberts. Proc of the American Society of
Clinical Oncology, Journal of Clinical Oncology 24(18S):
#5005, 2006.
11/15/97
12/01/01
*Presented
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
ABSTRACTS PUBLISHED/PRESENTED
*S9701
(2153)
Relationship between pretreatment CA-125 level and
risk of relapse in advanced ovarian cancer (AOC) patients
in a complete clinical response (CCR) who received
“maintenance therapy”. PY Liu, DS Alberts, BJ Monk,
M Brady, M Markman. Proc of the American Society
of Clinical Oncology, Journal of Clinical Oncology
23(16S):458S (#5013), 2005.
GYN
11/15/97
12/1/01
S9720
(2046)
Paclitaxel and carboplatin with amifostine in advanced,
recurrent, or refractory endometrial adenocarcinoma: a
phase II study of the Southwest Oncology Group.
SA Scudder, PY Liu, SP Wilcynski, HO Smith, C Jiang,
AV Hallum III, GB Smith, EV Hannigan, M Markman,
DS Alberts. Gynecologic Oncology 96:610-615, 2005.
GYN
2/15/98
7/15/01
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
9106
(1871)
Randomized phase II trial of two high dose chemotherapy
GYN
regimens with stem cell transplantation for the treatment of
advanced ovarian cancer in first remission or chemosensitive
relapse: a Southwest Oncology Group study. PJ Stiff,
EJ Shpall, PY Liu, SP Wilczynski, NS Callander, SA Scudder,
AR Jazieh, W Samlowski, J McCoy, DS Alberts.
Gynecologic Oncology 94:98-106, 2004.
7/1/93
11/15/97
9318/9405
(2007)
Recombinant human erythropoietin as an adjunct to
radiation therapy and cisplatin for stage IIB-IVA carcinoma
of the cervix: a Southwest Oncology Group study.
RS Lavey, PY Liu, BE Greer, WR Robinson, PC Chang,
RB Wynn, ME Conrad, C Jiang, M Markman, DS Alberts.
Gynecologic Oncology 95:145-151, 2004.
12/15/94
3/1/99
9324
(2091)
Phase II trial of vinorelbine for relapsed ovarian cancer.
GYN
A Southwest Oncology Group study. ML Rothenberg,
PY Liu, S Wilczynski, WA Nahhas, GL Winakur, C Jiang,
CM Moinpour, B Lyons, GR Weiss, JH Essell, HO Smith,
M Markman, DS Alberts. Gynecologic Oncology 95:506-512,
2004.
3/15/95
7/1/97
9326
(2008)
Long-term follow-up of a phase II trial of oral altretamine for
GYN
consolidation of clinical complete remission in women with
stage III epithelial ovarian cancer in the Southwest Oncology
Group. DS Alberts, C Jiang, PY Liu, S Wilczynski, M Markman,
ML Rothenberg. International Journal of Gynecologic Cancer
14:224-228, 2004.
9/1/93
7/1/97
GYN
ABSTRACTS PUBLISHED/PRESENTED
8797
(2127)
Rethinking the use of chemotherapy and radiation after
radical hysterectomy: a clinical-pathologic analysis of
SWOG 8797/GOG 109. SS Im, BJ Monk, J Wang,
RJ Stock, WA Peters III, PY Liu, RJ Barrett II, JS Berek,
L Souhami, P Grisby, W Gordon, DS Alberts.
Gynecologic Oncology 92:396 (#8), 2004.
GYN
9/1/90
12/15/96
*S9717
(2073)
Tirapazamine plus cisplatin in advanced or recurrent
squamous or adenosquamous carcinoma of the uterine
cervix: a phase II study of the Southwest Oncology Group
(SWOG). HO Smith, C Jiang, GR Weiss, AV Hallum III,
PY Liu, AM Miller, DR Gandara, M Markman, DS Alberts.
Gynecologic Oncology 92:416 (#49), 2004.
GYN
8/15/98
8/15/00
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
S9047
(2489)
Adjuvant treatment for early ovarian cancer: a
randomized phase III trial of intraperitoneal 32P or
intravenous cyclophosphamide and displatin – a
gynecologic oncology group study. RC Young,
MF Brady, RK Nieberg, HJ Long, AR Mayer,
SS Lenz, J Hurteau, DS Alberts. Journal of Clinical
Oncology 21 (23):4350-4355, 2003. PMID: 146454424
GYN
1/1/91
3/14/94
S9238
(2487)
Phase III trial of paclitaxel at two dose levels, the higher
dose accompanied by filgrastim at two dose levels in
platinum-pretreated epithelial ovarian cancer: an intergroup study. GA Omura, MF Brady, KY Look, HE
Averette, JE Delmore, HJ Long, S Wadler, G Spiegel,
SG Arbuck. Journal of Clinical Oncology 21(15):28102814, 2003.
GYN
1/15/93
2/6/95
S9618
(1769)
Phase II trial of single agent carboplatin followed by dose
GYN
intense paclitaxel, followed by maintenance paclitaxel therapy
in stage IV ovarian, fallopian tube and peritoneal cancers: a
Southwest Oncology Group trial. M Markman, T Glass, HO
Smith, KD Hatch, GR Weiss, SA Taylor, JW Goodwin, DS Alberts.
Gynecologic Oncology 88:282-288, 2003.
10/1/96
9/15/99
S9619
(1842)
Combined intraperitoneal and intravenous chemotherapy for
women with optimally debulked ovarian cancer: Results
from an Intergroup Phase II trial. ML Rothenberg,
PY Liu, PS Braley, SP Wilczynski, EV Hannigan, S Wadler,
G Stuart, C Jiang, M Markman, DS Alberts.
Journal of Clinical Oncology 21(7):1313-1319, 2003.
GYN
5/15/96
5/15/98
S9701
(1969)
Phase III randomized trial of 12 versus 3 months of
maintenance paclitaxel in patients with advanced ovarian
cancer after complete response to platinum and
paclitaxel-based chemotherapy: a Southwest Oncology
Group and Gynecologic Oncology Group trial. M Markman,
PY Liu, S Wilczynski, B Monk, LJ Copeland, RD Alvarez,
C Jiang, D Alberts. Journal of Clinical Oncology
21(13):2460-2465, 2003.
GYN
11/15/97
12/1/01
12/15/94
3/1/99
ABSTRACTS PUBLISHED/PRESENTED
S9318
(2067)
*Presented
Recombinant human erythropoietin (EPO) as an adjunct to
GYN
radiation therapy and cisplatin for stage IIB-IVA carcinoma
of the cervix: a Southwest Oncology Group study. RS Lavey,
PY Liu, BE Greer, WR Robinson III, CC Pui, RB Wynn, ME
Conrad, C Jiang, M Markman, DS Alberts. Int Journal of
Rad Onc Bio Phy 57(2) Suppl:S190-S191 (#110), 2003.
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8412
(2012)
Improved therapeutic index of carboplatin plus
cyclophosphamide versus cisplatin plus
cyclophosphamide: Final report by the Southwest
Oncology Group of a phase III randomized trial in
stages III and IV ovarian cancer. DS Alberts, S Green,
EV Hannigan, R O'Toole, D Stock-Novack, P Anderson,
EA Surwit, VK Malviya, WA Nahhas, CJ Jolles.
Classic Papers and Current Comments 7(1):41-52, 2002.
GYN
11/25/85
05/01/89
8412/8501
(1808)
Prediction of the need for red cell transfusion in newly
diagnosed ovarian cancer patients undergoing platinumbased treatment. D Heddens, DS Alberts, EV Hannigan,
SD Williams, D Garcia, DJ Roe, J Bell, RD Alvarez.
Gynecologic Oncology 86:239-243, 2002.
GYN
8797
(2011)
Concurrent chemotherapy and pelvic radiation therapy
compared with pelvic radiation therapy alone as adjuvant
therapy after radical surgery in high-risk early-stage cancer
of the cervix. WA Peters III, PY Liu, RJ Barrett II, RJ Stock,
BJ Monk, JS Berek, L Souhami, P Grigsby, W Gordon Jr,
DS Alberts. Classic Papers and Current Comments 7(1):
174-181, 2002.
GYN
9/1/90
12/15/96
9227
(2013)
Phase III trial of standard-dose intravenous cisplatin plus
paclitaxel versus moderately high-dose carboplatin
follow by intravenous paclitaxel and intraperitoneal
cisplatin in small volume stage III ovarian carcinoma:
an Intergroup study of the Gynecologic Oncology Group,
Southwestern Oncology Group, and Eastern Cooperative
Oncology Group. M Markman, BN Bundy, DS Alberts,
JM Fowler, DL Clark-Pearson, LF Carson, S Wadler,
J Sickel. Classic Papers and Current Comments 7(1):92-99,
2002.
GYN
12/15/92
4/3/95
9521
(1744)
Correlation of p53 immunostaining in primary and residual
GYN
ovarian cancer at the time of positive second-look laparotomy,
and its prognostic role: a Southwest Oncology Group ancillary
study. D Hawes, PY Liu, FM Muggia, S Wilczynski, R Cote,
J Felix, K Terada, RJ Belt, DS Alberts.
Gynecologic Oncology 87:17-23, 2002.
3/1/96
11/1/98
3/15/95
7/1/97
ABSTRACTS PUBLISHED/PRESENTED
*9324
HRQL outcomes in a phase II trial for patients with
GYN
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
(1904)
recurrent ovarian cancer: was palliation achieved?
CM Moinpour, B Lyons, S McCoy, GL Winakur,
PY Liu, ML Rothenberg. Quality of Life Research
11(7):660 (#157), 2002.
S9619
(1788)
Excellent 2-year survival in women with optimally-debulked
GYN
ovarian cancer treated with intraperitoneal and intravenous
chemotherapy: a SWOG-ECOG-NCIC study (S9619).
ML Rothenberg, P Liu, S Wilczynski, PS Braly, S Wadler,
G Stuart, EV Hannigan, AJ Bonebrake, DS Alberts, M Markman.
Proc of the American Society of Clinical Oncology 21:203a
(#809), 2002.
5/15/96
5/15/98
S9701
(1805)
Phase 3 randomized trial of 12 versus 3 months of singleagent paclitaxel in patients with advanced ovarian cancer
who attained a clinically-defined complete response to
platinum/paclitaxel-based chemotherapy, a Southwest
Oncology Group and Gynecologic Oncology Group trial.
M Markman, PY Liu, S Wilczynski, BJ Monk, L Copeland,
D Alberts. Gynecologic Oncology 84:479 (#1), 2002.
11/15/97
12/1/01
*Presented
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8835
(1945)
Phase II selection designs. PY Liu. In: Handbook of
Statistics in Clinical Oncology J Crowley, ed. MarcelDekker, New York, 119-127, 2001.
GYN
12/1/88
1/1/94
9227
(1657)
Phase III trial of standard-dose intravenous cisplatin plus
paclitaxel versus moderately high-dose carboplatin
follow by intravenous paclitaxel and intraperitoneal
cisplatin in small volume stage III ovarian carcinoma:
an Intergroup study of the Gynecologic Oncology Group,
Southwest Oncology Group, and Eastern Cooperative
Oncology Group. M Markman, BN Bundy, DS Alberts,
JM Fowler, DL Clark-Pearson, LF Carson, S Wadler,
J Sickel. Journal of Clinical Oncology 19(4):1001-1007,
2001
GYN
12/15/92
4/3/95
9326
(1696)
Phase II trial of oral altretamine for consolidation of clinical
GYN
complete remission in women with stage III epithelial ovarian
cancer: a Southwest Oncology Group trial (SWOG-9326).
ML Rothenberg, PY Liu, S Wilczynski, EV Hannigan, SA
Weiner, GR Weiss, VJ Hunter, JA Chapman, A Tiersten, PC
Kohler, DS Alberts. Gynecologic Oncology 82:317-322, 2001.
9/1/93
7/1/97
12/15/94
3/1/99
2/15/98
7/15/00
ABSTRACTS PUBLISHED/PRESENTED
9318
(1733)
Recombinant human erythropoietin (EPO) as an adjunct to
radiation therapy (RT) and cisplatin for stage IIB-IVA
carcinoma of the cervix: a Southwest Oncology Group
(SWOG) study. RS Lavey, PY Liu, BE Greer, PC Cheng,
WR Robinson, BJ Monk, RB Wynn, ME Conrad, DS Alberts.
Gynecologic Oncology 80(2):276-277 (#6), 2001.
*S9720
(1723)
Paclitaxel (PCT) and carboplatin (C) with amifostine (A)
GYN
in advanced or recurrent endometrial cancer: a Southwest
Oncology Group trial (S9720). SA Scudder, PY Liu, HO Smith,
SP Wilczynski, EV Hannigan, DS Alberts. Proc of the
American Society of Clinical Oncology 20:205a (#819), 2001.
*Presented
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8835
(1600)
Analysis of MLH1 and MSH2 expression in ovarian cancer
before and after platinum drug-based chemotherapy.
G Samimi, D Fink, NM Varki, A Husain, WJ Hoskins, DS
Alberts, SB Howell. Clinical Cancer Research 6:1415-1421,
2000.
GYN
12/1/88
1/1/94
8797
(1545)
Concurrent chemotherapy and pelvic radiation therapy
compared with pelvic radiation therapy alone as adjuvant
therapy after radical surgery in high-risk early stage
cancer of the cervix. WA Peters III, PY Liu, RJ Barrett,
RJ Stock, BJ Monk, JS Berek, L Souhami, P Grigsby,
W Gordon Jr, DS Alberts. Journal of Clinical Oncology
18(8):1606-1613, 2000.
GYN
9/1/90
12/15/96
ABSTRACTS PUBLISHED/PRESENTED
9318
(1642)
Recombinant human erythropoietin (EPO) as an adjunct to
concurrent radiation therapy (RT) and cisplatin for stage
IIB-IVA carcinoma of the cervix: a Southwest Oncology
Group study. RS Lavey, PY Liu, BE Greer, PC Cheng,
WR Robinson, BJ Monk, RB Wynn, ME Conrad, DS Alberts.
Radiotherapy & Oncology , 56(Suppl 1):S92 (#330), 2000.
GYN
12/15/94
3/1/99
*9326
(1616)
Altretamine (Hexalen) consolidation for patients with stage
III epithelial ovarian cancer in clinical complete remission: a
Southwest Oncology Group trial (S9326). DS Alberts, ML
Rothenberg, PY Liu, SA Weiner, VJ Hunter, A Tiersten, PC
Kohler, EV Hannigan, S Wilczynski. Proc of the American
Society of Clinical Oncology 19:384a (#1520), 2000.
GYN
9/1/93
7/1/97
9326
(1562)
Phase II trial of oral altretamine for women with stage III
epithelial ovarian cancer in clinical complete remission: a
Southwest Oncology Group study (S9326). ML Rothenberg,
PY Liu, SA Weiner, V Hunter, A Tiersten, PC Kohler, EV
Hannigan, S Wilczynski, DS Alberts. Gynecologic Oncology
76(2):263-264 (#126), 2000.
GYN
9/1/93
7/1/97
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8695
(1415)
Randomized comparison of fluorouracil plus cisplatin
GYN
versus hydroxyurea as an adjunct to radiation therapy
in stages IIB-IVA carcinoma of the cervix with negative
para-aortic lymph nodes: A Gynecologic Oncology Group
and Southwest Oncology Group study. CW Whitney, W Sause,
BN Bundy, JH Malfetano, EV Hannigan, WC Fowler, Jr,
DL Clarke-Pearson, S Liao. Journal of Clinical Oncology
17(5):1339-1348, 1999.
7/15/87
12/15/90
8835
(1937)
False positive rates of randomized phase II designs.
PY Liu, M LeBlanc, M Desai. Controlled Clinical Trials
20:343-352, 1999.
GYN
12/1/88
1/1/94
9212
(1522)
Phase II trial of oral etoposide in recurrent or refractory
endometrial adenocarcinoma: A Southwest Oncology Group
study. EA Poplin, PY Liu, JE Delmore, S Wilczynski,
DF Moore, RK Potkul, BA Fine, EV Hannigan, DS Alberts.
Gynecologic Oncology 74:432-435, 1999.
GYN
5/15/94
1/15/97
ABSTRACTS PUBLISHED/PRESENTED
*8797
(1496)
Cisplatin, 5-Fluorouracil plus radiation therapy are superior to GYN
radiation therapy as adjunctive therapy in high-risk, early-stage
carcinoma of the cervix after radical hysterectomy and pelvic
lymphadenectomy; report of a phase III intergroup study. WA
Peters, PY Liu, R Barrett, W Gordon, R Stock, JF Berek, PH DiSaia,
L Souhami, P Grigsby, DS Alberts. Proc of the Society of
Gynecologic Oncologists #1, 1999.
9/1/90
12/15/96
*9047
(1647)
Randomized clinical trial of adjuvant treatment of women
with early (Figo-I-IIA high risk) ovarian cancer-GOG #95.
RC Young, MF Vrady, RM Nieberg, HJ Long, A Mayer,
SS Lentz, J Hurteau, DS Alberts. Proc of the American
Society of Clinical Oncology 18:357a (#1376), 1999.
GYN
1/1/91
3/14/94
9324
(1512)
A phase II trial of vinorelbine in relapsed and refractory
ovarian cancer - A Southwest Oncology Group study
(SWOG-9324). ML Rothenberg, PY Liu, WA Nahhas,
GR Weiss, LE Schroder, L Elias, S Wilczynski, G Winakur,
DS Alberts. Proc of the American Society of Clinical
Oncology 18:383a (#1480), 1999.
GYN
3/15/95
7/1/97
9521
(1509)
Concordance of pre-and post- chemotherapy p53 immunostaining, and its prognostic significance in epithelial ovarian
cancer (EOC) receiving intraperitoneal (IP) consolidation:
GYN
3/1/96
11/1/98
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
A Southwest Oncology Group study (SWOG-9521). L Pandit,
PY Liu, FM Muggia, JC Felix, D Hawes, KY Terada, JC Paradelo,
RJ Cote, DS Alberts. Proc of the American Society of
Clinical Oncology 18:382a (#1475), 1999.
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8412
(1521)
Chemotherapy in advanced ovarian cancer: four systematic
meta-analyses of individual patient data from 37 randomized
trials. DS Alberts, PY Liu, SWOG representatives.
British Journal of Cancer 78(11):1479-1487, 1998.
GYN
11/25/85
5/1/89
9132/9225
(1369)
13-cis-retinoic acid or all-trans-retinoic acid plus
interferon-_ in recurrent cervical cancer: A Southwest
Oncology Group phase II randomized trial. GR Weiss,
PY Liu, DS Alberts, Y Peng, E Fisher, MJ Xu, SA
Scudder, LH Baker, DF Moore Jr, SM Lippman.
Gynecologic Oncology 71:386-390, 1998.
GYN
9/15/92
5/15/96
ABSTRACTS PUBLISHED/PRESENTED
9212
(1373)
Phase II trial of oral etoposide in recurrent or refractory
GYN
endometrial adenocarcinoma (SWOG 9212). EA Poplin,
PY Liu, J Delmore, S Wilczynski, D Alberts. Proc of the
American Society of Clinical Oncology 17:373a (#1436), 1998.
5/15/94
1/15/97
*9227
(1374)
Randomized phase 3 study of intravenous (IV) cisplatin
GYN
(CIS)/paclitaxel (PAC) versus moderately high dose IV
carboplatin (CARB) followed by IV PAC and intraperitoneal
(IP) CIS in optimal residual ovarian cancer (OC): An Intergroup
trial (GOG, SWOG, ECOG). M Markman, B Bundy, J Benda,
D Alberts, S Wadler, J Fowler, D Clark-Pearson, LF Carson.
Proc of the American Society of Clinical Oncology 17:361a
(#1392), 1998.
12/15/92
4/3/95
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
ABSTRACTS PUBLISHED/PRESENTED
9047
(1316)
Randomized clinical trial of adjuvant treatment of women
with early (FIGO I-IIA high risk) ovarian cancer - GOG #95.
RC Young, MF Brady, RM Nieberg, HJ Long, A Mayer,
SS Lentz, J Hurteau, DS Alberts. Sixth Biennial Meeting,
International Gynecologic Cancer Society Fukuoka, Japan,
October, 1997.
GYN
1/1/91
3/14/94
*9132
(1242)
A randomized phase II trial of 13-cis-retinoic acid (CRA) or
all-trans-retinoic acid (ATRA) plus interferon alpha 2a (IFN)
for metastatic or recurrent squamous/adenosquamous
carcinoma of the uterine cervix: a Southwest Oncology
Group study. GR Weiss, PY Liu, DS Alberts, DR Gandara,
LH Baker, HE Hynes. American Society of Clinical Oncology
16:355a (#1268), 1997.
Gyn
9/15/92
5/15/96
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8501
(1171)
Intraperitoneal cisplatin plus intravenous cyclophosphamide
versus intravenous cisplatin plus intravenous
cyclophosphamide for stage III ovarian cancer.
DS Alberts, PY Liu, EV Hannigan, R O'Toole, SD Williams,
JA Young, EW Franklin, DL Clarke-Pearson, VK Malviya,
B DuBeshter, MD Adelson, WJ Hoskins. New England
Journal of Medicine 335(26):1950-1955, 1996.
GYN
5/9/86
7/15/92
8835
(1112)
Intraperitoneal mitoxantrone or floxuridine: Effects on
time-to-failure and survival in patients with minimal
residual ovarian cancer after second-look laparotomyA randomized phase II study by the Southwest Oncology
Group. FM Muggia, PY Liu, DS Alberts, DL Wallace,
RV O'Toole, KY Terada, EW Franklin, GW Herrer, DA
Goldberg, EV Hannigan. Gynecologic Oncology
61:395-402, 1996.
GYN
12/1/88
1/1/94
8918
(1132)
A phase II trial of piroxantrone in endometrial cancer:
Southwest Oncology Group study 8918. VK Malviya,
PY Liu, DA Goldberg, A Hantel, RV O'Toole, RW Roach,
ME Conrad, DS Alberts. Anti-Cancer Drugs 7(5):527-530,
1996.
GYN
7/1/91
5/1/94
ABSTRACTS PUBLISHED/PRESENTED
*8501
(INT-0051)
(779)
Phase III study of IP cisplatin plus IV cyclophosphamide
vs IV cisplatin plus IV cyclophosphamide in optimal disease
stage III ovarian cancer: An Intergroup study 0051 (SWOGGOG-ECOG). DS Alberts, PY Liu, EV Hannigan, R O'Toole,
SD Williams, J Young, EW Franklin, D Clarke-Pearson, VK
Malviya, B DuBeshter, W Hoskins, M Adelson, RD Alvarez,
S Vogel, J O'Sullivan, DJ Garcia, D Sparks, ML Rothenberg.
Society of Gynecologic Oncologists Abstract Book (#1):40,
1996.
GYN
5/9/86
7/15/92
*9238
(1151)
A randomized trial of paclitaxel (T) at 2 dose levels and
filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated
epithelial ovarian cancer (OVCA): A Gynecologic Oncology
Group, SWOG, NCCTG and ECOG study. GA Omura, MF
Brady, JE Delmore, HJ Long, KY Look, HE Averette, S
Wadler, G Spiegel. American Society of Clinical Oncology
15:280 (#755), 1996.
GYN
1/15/93
2/6/95
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8745
(1006)
Chemoprevention of cervical cancer with folic acid:
A phase III SWOG Intergroup study. JM Childers,
J Chu, LF Voigt, P Feigl, HK Tamimi, EW Franklin,
DS Alberts, FL Meyskens Jr. Cancer Epidemiology,
Biomarkers, & Prevention 4:155-159, 1995.
GYN
CCR
12/1/88
6/15/90
8904
(1043)
A phase II trial of piroxantrone in advanced ovarian
carcinoma after failure of platinum-based chemotherapy:
Southwest Oncology Group study 8904. KS Albain, PY Liu,
A Hantel, EA Poplin, RV O'Toole, JL Wade III, AM Maddox,
DS Alberts. Gynecologic Oncology 57:407-411, 1995.
GYN
12/1/90
2/15/93
ABSTRACTS PUBLISHED/PRESENTED
*8412
(1031)
CA-125 concentration 8 weeks after treatment initiation
GYN
independently predicts survival in patients with advanced
epithelial ovarian cancer: A Southwest Oncology Group
(SWOG) study. PY Liu, DS Alberts, M Federico, EV Hannigan,
DJ Garcia, ML Rothenberg, RT Dorr. ASCO 14:266 (#735), 1995.
11/25/85
5/1/89
*8501
(INT-0051)
(1080)
Phase III study of intraperitoneal (IP) cisplatin (CDDP)/
intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV
CPA in patients (pts) with optimal disease stage III ovarian
cancer: A SWOG-GOG-ECOG Intergroup Study (INT-0051).
DS Alberts, PY Liu, EV Hannigan, R O'Toole, SD Williams,
J Young, EW Franklin, D Clarke-Pearson, VK Malviya,
B DuBeshter, W Hoskins, M Adelson, RD Alvarez, S Vogel,
J O'Sullivan, DJ Garcia, D Sparks, ML Rothenberg.
ASCO 14:273 (#760), 1995.
GYN
5/9/86
7/15/92
*8835
(1084)
Elevated serum CA-125: An adverse prognostic
factor for survival in epithelial ovarian cancer (EOC)
with minimal residual disease after second-look
laparotomy (SLL). F Muggia, PY Liu, DS Alberts,
K Terada, RJ Belt, HJ Schmidt, TW Pollock, EB Weiser,
D Blayney, D Wallace, R O'Toole. ASCO 14:270 (#750),
1995.
GYN
12/1/88
1/1/94
*Presented
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8412
(919)
Cisplatin versus carboplatin in advanced ovarian cancer:
An economic analysis. D Alberts, E Hannigan, R Cannetta,
R O'Toole, V Malviya, E Surwit, W Nahhas, C Jolles, J
Jacobs, S Pashko. Pharmacy and Therapeutics 19(7):
692-706, 1994.
GYN
11/25/85
5/1/89
8732
(881)
Phase II trial of amonafide in patients with advanced
metastatic or recurrent endometrial adenocarcinoma:
A Southwest Oncology Group study. VK Malviya, P Liu,
R O'Toole, DS Alberts, E Surwit, S Rosenoff, JH Ward,
A Yu, J O'Sullivan, JB Craig. AJCO 17(1):37-40, 1994.
GYN
3/88
3/1/91
12/01/88
01/01/94
ABSTRACTS PUBLISHED/PRESENTED
8835
(963)
Intraperitoneal (IP) mitoxantrone vs. intraperitoneal
floxuridine in ovarian cancer patients with minimal
residual disease after second-look surgery, a
randomized phase II pilot. F Muggia, D Alberts,
P Liu, K Terada, D Wallace. ASCO 13:249 (#782), 1994.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8412
(519)
Analysis of patient age as an independent prognostic
factor for survival in a phase III study of cisplatincyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian
cancer. A Southwest Oncology Group study. DS
Alberts, S Dahlberg, SJ Green, D Garcia, EV Hannigan,
R O'Toole, D Stock-Novack, EA Surwit, VK Malviya,
CJ Jolles. Cancer 71(2):618-627, 1993.
GYN
11/25/85
05/01/89
8412
(911)
Results of a Southwest Oncology Group phase III
trial of carboplatin plus cyclophosphamide versus
cisplatin plus cyclophosphamide in advanced
ovarian cancer. EV Hannigan, S Green, DS Alberts,
R O'Toole, E Surwit. Oncology 50 (Suppl 2):2-9, 1993.
GYN
11/25/85
05/01/89
9047
(INT)
(1029)
Localized ovarian cancer in the elderly. The Gynecologic
Oncology Group experience. RC Young, MF Brady,
LA Walton, HD Homesley, HE Averette, HJ Long.
Cancer Supplement 71(2):601-605, 1993.
GYN
1/1/91
3/14/94
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8092
(386)
A Southwest Oncology Group study on the use
of a human tumor cloning assay for predicting
response in patients with ovarian cancer.
DD Von Hoff, R Kronmal, SE Salmon, J Turner,
JB Green, JS Bonorris, EL Moorhead, HE Hynes,
RP Pugh, RJ Belt, DS Alberts. Cancer 67(1):20-27,
1991.
GYN
11/21/80
10/03/84
8320
(389)
Phase II study of fludarabine phosphate (NSC-312887)
in patients with advanced endometrial cancer: A
Southwest Oncology Group study. DD Von Hoff,
S Green, DS Alberts, DL Stock-Novack, EA Surwit,
TP Miller, RL Stephens. AJCO 14(3):193-194, 1991.
GYN
06/01/84
03/01/88
8408
(392)
Esorubicin in advanced endometrial cancer: An ineffective and potentially toxic therapy. A Southwest
Oncology Group study. JB Green, III, S Green, RV
O'Toole, DS Alberts, WA Nahhas, DL Wallace. IND
9:191-193, 1991.
GYN
06/11/84
05/01/88
8412
(487)
Chemotherapy in advanced ovarian cancer; an overview
of randomized clinical trials. Advanced ovarian cancer
trialists group. British Medical Journal 303:884-893, 1991.
GYN
12/25/85
05/01/89
8500
(394)
Second-line treatment of advanced measurable ovarian
cancer with iproplatin: A Southwest Oncology Group
study. G Weiss, S Green, DS Alberts, JT Thigpen, HE
Hynes, K Hanson, HI Pierce, LH Baker, JW Goodwin.
EJCO 27(2):135-138, 1991.
GYN
08/01/86
11/15/88
12/01/88
Open
ABSTRACTS PUBLISHED/PRESENTED
8835
(414)
CA-125: A predictor of outcome from intraperitoneal (IP)
therapy in Southwest Oncology Group study 8835. C
Truesdal, FM Muggia, DS Alberts, PY Liu, J O'Sullivan,
D Wallace. ASCO 10:195 (#644), 1991.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8321
(316)
A phase II trial of cisplatin and 5-fluorouracil with
allopurinolfor recurrent or metastatic carcinoma of
the uterine cervix:A Southwest Oncology Group trial.
GR Weiss, S Green, EV Hannigan, JG Boutselis,
EA Surwit, DL Wallace, DS Alberts. Gyn Onc 37:
354-358, 1990.
GYN
12/07/84
05/01/88
8321
(317)
A phase II trial of carboplatin for recurrent or metastatic
squamous carcinoma of the uterine cervix: A Southwest
Oncology Group study. GR Weiss, S Green, EV
Hannigan, JG Boutselis, EA Surwit, DL Wallace,
DS Alberts. Gyn Onc 39:332-336, 1990.
GYN
12/07/84
05/01/88
8328
(319)
Phase II study of fludarabine phosphate (NSC-312887)
patients with advanced cervical cancer. A Southwest
in Oncology Group study. DD Von Hoff, S Green, EA
Surwit, EV Hannigan, DS Alberts. AJCO 13(5):433-435,
1990.
GYN
06/01/84
03/18/87
8407
(322)
Carboplatin therapy in advanced endometrial cancer.
A Southwest Oncology Group study. JB Green III,
S Green, DS Alberts, R O'Toole, EA Surwit, JW
Noltimier. Obst & Gyn 75(4):696-700, 1990.
GYN
07/20/84
09/01/87
8407
Carboplatin therapy in advanced endometrial cancer: A
Southwest Oncology Group phase II study. JB Green,
DS Alberts, R O'Toole, EA Surwit, JW Noltimier. In:
Carboplatin (JM-8): Current Perspectives and Future
Directions , PA Bunn, R Canetta, RF Ozols, M
Rozencweig (Eds.), W.B. Saunders Company, pp.
113-121, 1990.
GYN
07/20/84
09/01/87
8412
(325)
Improved efficacy of carboplatin plus cyclophosphamide
versus cisplatin plus cyclophosphamide: Preliminary
report by the Southwest Oncology Group of a phase III
randomized trial in stages III and IV suboptimal ovarian
cancer. DS Alberts, SJ Green, EV Hannigan, R O'Toole,
N Mason-Liddil, EA Surwit, D Stock-Novack, R Goldberg,
VK Malviya, WA Nahhas, RP Pugh, JT Guy, SR Dakhil.
In: Carboplatin (JM-8): Current Perspectives and Future
Directions , PA Bunn, R Canetta, RF Ozols, and M
Rozencweig (Eds.), W.B. Saunders Company, pp. 163164, 1990.
GYN
11/25/85
05/01/89
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
8412
(359)
Assessment of treatment costs for carboplatin and
cisplatin. E Hannigan, D Alberts, S Green, R O'Toole,
N Mason-Liddil, E Surwit, D Stock-Novack, R Goldberg,
V Malviya, W Nahhas, R Canetta, R Thomas. ASCO
9:337 (#1305), 1990.
GYN
11/25/85
05/01/89
8412
(360)
Relationship between serum CA-125 levels at chemotherapy courses 3 and 6 and the outcome of second-look
surgery status in advanced ovarian cancer. DS Alberts,
PY Liu, E Hannigan, EA Surwit, J O'Sullivan, D Garcia,
M Richardson, S Williams, J Young, R O'Toole. AACR
31:189 (#1121), 1990.
GYN
11/25/85
05/01/89
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7925
Randomized phase III trial of chemoimmunotherapy
in patients with previously untreated stages III & IV
suboptimal disease in ovarian cancer: A Southwest
Oncology Group study. DS Alberts, N Mason-Liddil,
RV O'Toole, TM Abbott, R Kronmal, RD Hilgers,
EA Surwit, HJ Eyre, LH Baker. Gyn Onc 32:8-15,
1989.
GYN
08/06/79
03/16/84
7925
Randomized phase III trial of chemoimmunotherapy
in patients with previously untreated stage III,
optimal disease ovarian cancer: A Southwest
Oncology Group study. DS Alberts, N Mason-Liddil,
RV O'Toole, TM Abbott, R Kronmal, RD Hilgers,
EA Surwit, HJ Eyre, LH Baker. Gyn Onc 32:16-21,
1989.
GYN
08/06/79
03/16/84
ABSTRACTS PUBLISHED/PRESENTED
8321
Phase II trial of cisplatin (CP) and 5-fluorouracil
(5FU) with or without allopurinol (ALL) for the
treatment of metastatic or recurrent squamous
carcinoma of the uterine cervix: A Southwest
Oncology Group study. GR Weiss, S Green,
D Stock-Novack, DS Alberts, R Giudice.
ASCO 8:158 (#616), 1989.
GYN
12/07/84
05/01/88
8407
Carboplatin therapy in advanced endometrial cancer:
A Southwest Oncology Group study. JB Green,
S Green, DS Alberts, R O'Toole, EA Surwit, JW
Noltimier. ASCO 8:155 (#605), 1989.
GYN
07/20/84
09/01/87
*8412
Improved efficacy of carboplatin (CarboP)/
cyclophosphamide (CPA) vs cisplatin (CisP)/CPA:
Preliminary report of a phase III, randomized trial
in stages III-IV, suboptimal ovarian cancer (OV CA).
D Alberts, S Green, E Hannigan, R O'Toole,
N Mason-Liddil, E Surwit, D Stock-Novack,
R Goldberg, V Malviya, W Nahhas. ASCO 8:151
(#588), 1989.
GYN
11/25/85
05/01/89
8500
A phase II study of the second-line treatment of
advanced ovarian cancer with iproplatin: A
Southwest Oncology Group study. GR Weiss,
S Green, D Stock-Novack, DS Alberts.
Submitted to the Sixth NCI EORTC Symposium
on New Drugs in Cancer Therapy, 317, 1989.
GYN
08/01/86
11/15/88
Charles A. Coltman, Jr., M.D.
198-24-5536
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988
_________________________________________________________________________________________________________
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8319
Phase II study of fludarabine phosphate (NSC-312887)
in patients with advanced ovarian cancer. A Southwest
Oncology Group study. DD Von Hoff, R Kronmal,
RV O'Toole, EA Surwit, JJ Hutton, DS Alberts. AJCO
(CCT) 11(2):146-148, 1988.
GYN
06/01/84
06/30/86
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987
________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7936
Phase II randomized trial of cisplatin chemotherapy
regimens in the treatment of recurrent or metastatic
squamous cell cancer of the cervix: A Southwest
Oncology Group study. DS Alberts, R Kronmal, LH
Baker, DL Stock-Novack, EA Surwit, JG Boutselis,
EV Hannigan. JCO 5(11):1791-1795, 1987.
GYN
11/19/79
11/14/83
8038
Phase II trial of vinblastine in previously treated patients
with ovarian cancer: A Southwest Oncology Group
study. EA Surwit, DS Alberts, RV O'Toole, V Graham,
EV Hannigan, RL Stephens, JG Boutselis. Gyn Oncol
28:14-19, 1987.
GYN
12/09/80
12/05/83
8103
Doxorubicin-cisplatin-vinblastine combination
chemotherapy of advanced endometrial carcinoma:
A Southwest Oncology Group phase II trial. DS
Alberts, NL Mason, RV O'Toole, RD Hilgers, SE Rivkin,
JG Boutselis, RP Pugh, VK Vaitkevicius, JB Green,
N Oishi. Gyn Onc 26:193-201, 1987.
GYN
12/07/81
01/19/84
8200
A phase II trial of vinblastine in patients with advanced
or recurrent endometrial carcinoma: A Southwest Oncology
Group study. JT Thigpen, R Kronmal, S Vogel, HE Hynes,
W Nahhas, RJ Belt, SP Balcerzak, RB Epstein, JJ Costanzi.
JCO 10(5):429-431, 1987.
GYN
03/31/82
09/27/85
Charles A. Coltman, Jr., M.D.
198-24-5536
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986
__________________________________________________________________________________________
PROTOCOL
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
DATE
PROTOCOL
ACTIVATED
DATE
PROTOCOL
CLOSED TO
PATIENT
ENTRY
__________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7706
Chemotherapy of drug resistant ovarian cancer.
A Southwest Oncology Group study. LR Laufman,
JB Green, DS Alberts, RB O'Toole, RD Hilgers,
DC Young, P Lin, SE Rivkin. JCO 4(9):1374-1379,
1986.
GYN
09/09/77
05/29/79
8028
Mitoxantrone and advanced squamous cell carcinoma
of the cervix. A Southwest Oncology Group study.
RD Hilgers, DD Von Hoff, RL Stephens, JG Boutselis.
Cancer Treat Rep 70(4):527-528, 1986.
GYN
10/20/80
10/03/84
8117
Phase II trial of bisantrene in previously treated
patients with ovarian carcinoma: A Southwest
Oncology Group study. JD Cowan, EA Surwit,
DS Alberts, SP Balcerzak, BA Neilan. Cancer
Treat Rep 70(3):423-424, 1986.
GYN
08/04/80
12/05/83
08/06/79
03/16/84
ABSTRACTS PUBLISHED/PRESENTED
*7925
Randomized Phase III trial of doxorubicin (D) +
cyclophosphamide (C) + BCG vs. DC + cisplatin (P)
vs. DC +P + BCG in stages III & IV ovarian cancer
(OV CA). D Alberts, N Mason, R O'Toole, R Kronmal,
R Hilgers, E Surwit, H Eyre, L Baker, J Boutselis,
S Rivkin, B Green, E Hannigan. ASCO 5:119
(#462), 1986.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
8028
Mitoxantrone in adenocarcinoma of the endometrium:
A Southwest Oncology Group study. RD Hilgers, DD
Von Hoff, RL Stephens, JG Boutselis, SE Rivkin. Cancer
Treat Rep 69(11):1329-1330, 1985.
GYN
10/20/80
10/03/84
8412
Phase I trial of carboplatin-cyclophosphamide and
iproplatin-cyclophosphamide in advanced ovarian
cancer: A Southwest Oncology Group study.
DS Alberts, N Mason, E Surwit, S Weiner, N Hammond,
G Deppe. Cancer Treat Rep 12(Supp A):1-10, 1985.
GYN
11/01/84
05/01/89
ABSTRACTS PUBLISHED/PRESENTED
7936
Combination chemotherapy for patients with
disseminated carcinoma of the uterine cervix.
L Baker, J Boutselis, D Alberts, E Surwit,
R Hilgers. ASCO, #C-465, 1985.
GYN
11/19/79
11/14/83
*8412
Phase I trial of carboplatin-cyclophosphamide and
iproplatin-cyclophosphamide in advanced ovarian
cancer: A Southwest Oncology Group study.
DS Alberts, N Mason, E Surwit, S Weiner, N Hammond,
G Deppe. Proc ECCO, Interferon Alpha-2 Symposium,
Stockholm, Sweden, June 19, 1985.
GYN
11/01/84
05/01/89
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7767
Phase II and pharmacokinetic study of high-dose methotrexate GYN
in the treatment of advanced gynecologic malignancy. A
Southwest Oncology Group trial. RD Hilgers, DS Alberts,
JC Standefer, BE Skipper, NJ Miles, J Borst. Gynecol Oncol
18:62-70, 1984.
7958
Amsacrine (m-AMSA) in squamous cell carcinoma of the
uterine cervix: A Southwest Oncology Group study.
RD Hilgers, SS Legha, JG Boutselis, EV Hannigan,
RL Stephens, BL Tranum, E Surwit. Cancer Treat Rep
68:443-444, 1984.
GYN
7958
m-AMSA and adenocarcinoma of the endometrium: A
Southwest Oncology Group study. RD Hilgers, SS Legha,
GA Johnston Jr, DS Alberts, RL Stephens, BL Tranum,
EV Hannigan. Invest New Drugs 2:335-338, 1984.
GYN
8028
Mitoxantrone in epithelial carcinoma of the ovary. A
Southwest Oncology Group study. RD Hilgers, DD Von Hoff,
SE Rivkin, DS Alberts. Am J Clin Oncol 7(5):499-501, 1984.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7868
Mitomycin C, bleomycin, vincristine, and cisplatin combination
therapy for advanced recurrent cervix cancer: A Southwest
Oncology Group pilot study. DS Alberts, EA Surwit. In:
3rd NCI-EORTC Symposium on New Drugs. Mitomycin-C.
New York: Raven Press, 127-134, 1983.
GYN
7958
m-AMSA in epithelial carcinoma of the ovary: A Southwest
Oncology Group study. RD Hilgers, SS Legha, FJ Panettiere,
DS Alberts. Am J Clin Oncol 6:277-279, 1983.
GYN
*8108/16/
17/18/19/
20/61/
8214
Southwest Oncology Group studies with Bisantrene.
CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller,
E Surwit, DS Alberts, RA Shildt, F Panettiere, GM Mills,
PB Wasserman, TM McDaniel. In: 13th International
Congress of Chemotherapy (Vienna, August 28-September
2, 1983). KH Spitzy, K Karrer, eds. Symposium Bisantrene
213:1-4, 1983.
Myeloma,
Lymphoma,
GYN, GI,
Melanoma,
Leukemia,
Sarcoma
ABSTRACTS PUBLISHED/PRESENTED
*7936
Treatment of primary and recurrent, advanced squamous cell
cancer of the cervix with mitomycin-D + Vincristine +
Bleomycin (MOB) plus cisplatin (PLAT). EA Surwit,
DS Alberts, S Aristizabal, KJ Deatherage, R Heusinkveld.
ASCO, #C-596, 1983.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7524
A randomized trial of Doxorubicin and Cyclophosphamide +
BCG vs. Doxorubicin and Cyclophosphamide therapy of
advanced ovarian cancer. DS Alberts, NL Mason, R O'Toole,
J Neff, R Hilgers, D Carlin, TE Moon. In: Immunotherapy of
Human Cancer. WD Terry, SA Rosenberg, eds. New York:
Elsevier-North Holland, 343-350, 1982.
GYN
ABSTRACTS PUBLISHED/PRESENTED
8092
Long distance transportation of specimens for human tumor
cloning. J Turner, DD Von Hoff, KD Swenerton, E Gafney,
SE Rivkin, CA Coltman Jr, AB Cruz. ASCO, #C-117, 1982.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
68
Mitomycin-C, bleomycin, vincristine, cis-platinum in the
treatment of advanced, recurrent squamous cell carcinoma of
the cervix. DS Alberts, PW Martimbeau, EA Surwit, N Oishi.
Cancer Clin Trials 4:313-316, 1981.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7706
Cis-platinum combination chemotherapy for drug
resistant ovarian carcinoma. D Alberts, R Hilgers,
T Moon, R O'Toole, F Mantz, P Martimbeau, R
Stephens, S Rivkin, N Mason. In: Cis-Platinum: Current
Status and New Developments . New York: Academic Press,
393-401, 1980.
GYN
7868
Mitomycin-C and bleomycin in the treatment of faradvanced cervical cancer: A Southwest Oncology
Group pilot study. LP Leichman, LH Baker, CR
Stanhope, MK Samson, RJ Fraile, VK Vaitkevicius,
R Hilgers. Cancer Treat Rep 64(10-11):1139-40, 1980.
GYN
7870
Mitomycin C and bleomycin in the treatment of
far-advanced cervical cancer: A Southwest
Oncology Group pilot study. LP Leichman, LH
Baker, CR Stanhope, MK Samson, RJ Fraile,
VK Vaitkevicius, R Hilgers. Cancer Treat Rep 64:
1139-1140, 1980.
GYN
Several
Studies
Gynecologic cancers. DS Alberts. In: Clinical Immunotherapy . AF LoBuglio, ed. New York: Marcel Dekker,
Immunology Series, Vol. II, 1980.
GYN
ABSTRACTS PUBLISHED/PRESENTED
?
Chemoimmunotherapy of advanced ovarian
cancer and the use of an in vitro clonogenic assay
to predict response to anticancer drug therapy.
DS Alberts. Current Optimum Strategies for
Clinical Chemotherapy (October 22-24, 1980).
New York: Chemotherapy Foundation, Inc.,
88, 1980.
GYN
7524
Randomized trial of chemotherapy versus chemoimmunotherapy for advanced ovarian carcinoma:
A preliminary report of a Southwest Oncology Group
study. DS Alberts, TE Moon. Immunotherapy of
Cancer: Present Status of Trials in Man, p. 13, April,
1980.
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
?
Ovarian carcinoma: an optimistic epilogue. RC Young.
Cancer Treat Rep 63(2):333-337, 1979.
GYN
7438
Phase II evaluation of cis-dichlorodiammineplatinum (II)
in advanced malignancies of the genitourinary and
gynecologic organs: A Southwest Oncology Group
study. A Rossof, R Talley, R Stephens, T Thigpen,
M Samson, C Groppe, Jr, H Eyre, R Fisher. Cancer
Treat Rep 63(9-10):1557-1564, 1979.
GI
GYN
7524
Randomized study of chemoimmunotherapy for
advanced ovarian carcinoma. A preliminary report
of a Southwest Oncology Group study. DS Alberts,
TE Moon, RA Stephens, H Wilson, N Oishi, RD
Hilgers, R O'Toole, JT Thigpen. Cancer Treat Rep
63(2):325-331, 1979.
GYN
7524
Chemoimmunotherapy for advanced ovarian carcinoma
with adriamycin cyclophosphamide + BCG: Early
report of a Southwest Oncology Group study. D
Alberts, SE Salmon, TE Moon. In: Recent Results in
Cancer Research 68:160-165, 1979.
GYN
7524
BCG as an adjuvant to Adriamycin-Cyclophosphamide
in the treatment of advanced ovarian carcinoma:
Ongoing analysis of a Southwest Oncology Group study.
D Alberts, T Moon, R O'Toole, J Neff, JT Thigpen, J
Blessing. In: Adjuvant Therapy of Cancer II , pp. 483-494,
1979.
GYN
7706
Combination chemotherapy for alkylator-resistant
ovarian carcinoma: A preliminary report of a
Southwest Oncology Group trial. DS Alberts,
RD Hilgers, TE Moon, PW Martimbeau, S Rivkin.
Cancer Treat Rep 63(2):301-305, 1979.
GYN
ABSTRACTS PUBLISHED/PRESENTED
7524
BCG as an adjuvant to adriamycin - cytoxan for
advanced ovarian cancer. D Alberts. International
Conference on the Adjuvant Therapy of Cancer
#38, 1979.
1
GYN
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7412
Mitomycin-C, vincristine, and bleomycin therapy
for advanced cervical cancer. LH Baker, M Opipari,
H Wilson, R Bottomley, CA Coltman, Jr. Obstetrics
& Gynecology 52(2):146-147, 1978.
GYN
7524
Chemoimmunotherapy for advanced ovarian carcinoma
with adriamycin-cyclophosphamide + BCG: Early
report of a Southwest Oncology Group study. DS Alberts,
SE Salmon, TE Moon. Recent Results Cancer Res 68:
160-165, 1978.
GYN
1
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
7524
Adjuvant immunotherapy with BCG of advanced ovarian
cancer: A preliminary report. DS Alberts. Proc Int'l
Conference on Adjuvant Therapy of Cancer, Tucson, AZ.
1977. In: Adjuvant Therapy of Cancer, pp. 327-334, 1977.
GYN
ABSTRACTS PUBLISHED/PRESENTED
7412
Mitomycin-C, vincristine and bleomycin in disseminated
squamous cell cancer of the uterine cervix. LH Baker
and M Opipari. ASCO, #C-21, 1977.
GYN
7438
Phase II evaluation of single high-dose cis-diamminedichloroplatinum (II) (NSC-119875, CACP) in gynecologic
*GYN) and genitourinary (GU) neoplasia. AH Rossof, RW
Talley and RL Stephens. AACR, #388, 1977.
GYN
GU
7524
Adjuvant immunotherapy of ovarian cancer: A preliminary
report. Proc. Intl. Conference on Adjuvant Therapy of
Cancer, Tucson, AZ, #26, 1977.
GYN
1
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
ABSTRACTS PUBLISHED/PRESENTED
*226
Profiromycin therapy for disseminated cancer of the cervix
and other organs. FJ Panettiere. ASCO, #C-39, 1976.
GYN
*549
Randomized evaluation of chlorambucil and melphalan in
advanced ovarian cancer. AE Rossof, BH Drukker, RW
Talley, J Torres, J Bonnet and RW Brownlee. ASCO, #C256, 1976.
GYN
1
SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964
_________________________________________________________________________________________________________
DATE
PROTOCOL
DATE
CLOSED TO
PROTOCOL
PROTOCOL
PATIENT
NUMBER
PUBLICATIONS (TITLE & CITATION)
DISEASE
ACTIVATED
ENTRY
_________________________________________________________________________________________________________
MANUSCRIPTS PUBLISHED/PRESENTED
?
Phase II studies of hydroxyurea (NSC-32065) in adults:
Urologic and gynecologic neoplasms. CD Howe, ML
Samuels. Cancer Chemotherapy Reports 40:47-48, 1964.
1
GU
GYN